SCIENTIFIC PROGRAMME
SESSION I
THE GENOMIC AND
EPIGENOMIC LANDSCAPE
OF CLL AND CLINICAL
CONSEQUENCES
SESSION II
THE ROLE OF BCR
ACTIVATION AND
SIGNALLING FOR CLL
SESSION III
THERAPEUTIC OPTIONS
FOR CLL
SESSION IV
LONG TERM FOLLOW
UP OF CLINICAL TRIALS
VERSUS REAL WORLD
DATA (OUTSIDE CLINICAL
TRIALS DATA-OCT)
SESSION V
THE INCREASING ROLE
OF THE LEUKAEMIC
MICROENVIRONMENT
SESSION VI
THERAPEUTIC OPTIONS 2 :
THE USE OF CELLULAR
AND NON-CELLULAR
IMMUNOTHERAPIES IN
CLL
SESSION VII
EFFICACY THROUGH
SAFETY
SESSION VIII
CLONAL HETEROGENEITY,
CLONAL EVOLUTION AND
MECHANISMS OF DRUG
RESISTANCE
SESSION IX
CONTRASTING
THERAPEUTIC CONCEPTS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES
these toxicities are “on target” (i.e., BTK dependent) or due to off-target effects. We believe
these pre-clinical models can offer preventive and therapeutic strategies for our patients.
Keywords : cardio-oncology, myocarditis, immune-related adverse events
References
1. Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J Med.
2016;375:1457-1467.
2. Moslehi J. The cardiovascular perils of cancer survivorship. N Engl J Med. 2013;368:1055-6.
3. Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S,
Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M,
Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M and Burger JA.
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled
registration trials. Haematologica. 2017;102:1796-1805.
4. Groarke JD, Cheng S and Moslehi J. Cancer-drug discovery and cardiovascular surveillance. N
Engl J Med. 2013;369:1779-81.
5. Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R,
Savage KJ, Michaud GF, Moslehi JJ and Brown JR. Ventricular arrhythmias and sudden death in patients
taking ibrutinib. Blood. 2017;129:2581-2584.
6. Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, Guha A, Rogers KA, Bhat S,
Byrd JC, Woyach JA, Awan F and Addison D. Hypertension and incident cardiovascular events following
ibrutinib initiation. Blood. 2019;134:1919-1928.
7. Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T,
Reddy NM, Funck-Brentano C, Brown JR, Roden DM and Moslehi JJ. Cardiovascular Toxicities Associated
With Ibrutinib. J Am Coll Cardiol. 2019;74:1667-1678.
8. Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule
S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A,
Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T and Burger JA. Incidence of
and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br J
Haematol. 2019;184:558-569.